Therapeutic inadequacy in spite of bioequivalency on replacing Fluctine[®] with Fluocim[®]

Jacqueline Albrecht, MD, Solothurn

Rolf H. Adler, Professor of Medicine, Medical Division Lory, University of Berne Medical School

At the beginning of October 1996, a 61-yearold woman with sleeping problems, loss of appetite, lack of drive and interest, difficulties with concentration and anxiety was prescribed 20 mg of Fluctine[®] daily. After 14 days the symptoms had subsided and she began to take up hobbies she had neglected for years. In 1998 physician and patient decided to change to 20 mg of the generic Fluocim[®] (daily dose costing CHF 2.75 rather than CHF 3.70). Eighteen days later the physician was surprised to find that the patient showed symptoms similar to those of October 1996. Convinced that the regression could not be due to the generic, the physician suggested keeping it on for another 14 days. Two weeks later the patient's condition was unchanged. Fluocim[®] was withdrawn and Fluctine[®] reinstated. After 14 days she was again symptom-free and has remained so for 14 months. A similar observation was reported by Hovaquimian[1].

The authors conclude on the need to check the patient's blood levels the next time such a case arises.

References

1 Hovaquimian T. Méd Hyg 1998;2229:2085-7.

Swiss Medical Weekly


Official journal of the Swiss Society of Infectious disease the Swiss Society of Internal Medicine the Swiss Respiratory Society

The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW's impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Impact factor Swiss Medical Weekly



Editorial Board Prof. Jean-Michel Dayer, Geneva Prof. Peter Gehr, Berne Prof. André P. Perruchoud, Basel Prof. Andreas Schaffner, Zurich (Editor in chief) Prof. Werner Straub, Berne Prof. Ludwig von Segesser, Lausanne

International Advisory Committee Prof. K. E. Juhani Airaksinen, Turku, Finland Prof. Anthony Bayes de Luna, Barcelona, Spain Prof. Hubert E. Blum, Freiburg, Germany Prof. Walter E. Haefeli, Heidelberg, Germany Prof. Nino Kuenzli, Los Angeles, USA Prof. René Lutter, Amsterdam, The Netherlands Prof. Claude Martin, Marseille, France Prof. Josef Patsch, Innsbruck, Austria Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors: http://www.smw.ch/set_authors.html



All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd. SMW Editorial Secretariat Farnsburgerstrasse 8 CH-4132 Muttenz

Manuscripts:	submission@smw.ch
Letters to the editor:	letters@smw.ch
Editorial Board:	red@smw.ch
Internet:	http://www.smw.ch
Internet:	http://www.smw.ch